These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38513080)

  • 1. Novel TLR4-Activating Vaccine Adjuvant Enhances the Production of
    Franco AR; Sadones O; Romerio A; Artusa V; Shaik MM; Pasco ST; Italia A; D'Amato S; Anguita J; Huebner J; Romero-Saavedra F; Peri F
    J Med Chem; 2024 Apr; 67(7):5603-5616. PubMed ID: 38513080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants.
    Romerio A; Gotri N; Franco AR; Artusa V; Shaik MM; Pasco ST; Atxabal U; Matamoros-Recio A; Mínguez-Toral M; Zalamea JD; Franconetti A; Abrescia NGA; Jimenez-Barbero J; Anguita J; Martín-Santamaría S; Peri F
    J Med Chem; 2023 Feb; 66(4):3010-3029. PubMed ID: 36728697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model.
    Gregg KA; Harberts E; Gardner FM; Pelletier MR; Cayatte C; Yu L; McCarthy MP; Marshall JD; Ernst RK
    Vaccine; 2018 Jun; 36(28):4023-4031. PubMed ID: 29861179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TLR4-derived non-cytotoxic, self-assembling peptide functions as a vaccine adjuvant in mice.
    Tandon A; Pathak M; Harioudh MK; Ahmad S; Sayeed M; Afshan T; Siddiqi MI; Mitra K; Bhattacharya SM; Ghosh JK
    J Biol Chem; 2018 Dec; 293(51):19874-19885. PubMed ID: 30385503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.
    Orr MT; Fox CB; Baldwin SL; Sivananthan SJ; Lucas E; Lin S; Phan T; Moon JJ; Vedvick TS; Reed SG; Coler RN
    J Control Release; 2013 Nov; 172(1):190-200. PubMed ID: 23933525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of TLR4 agonist activity: formulation effects.
    Misquith A; Fung HW; Dowling QM; Guderian JA; Vedvick TS; Fox CB
    Colloids Surf B Biointerfaces; 2014 Jan; 113():312-9. PubMed ID: 24121074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a Self-Assembling Small-Molecule Cancer Vaccine Adjuvant with an Improved Toxicity Profile.
    Zhuo SH; Noda N; Hioki K; Jin S; Hayashi T; Hiraga K; Momose H; Li WH; Zhao L; Mizukami T; Ishii KJ; Li YM; Uesugi M
    J Med Chem; 2023 Sep; 66(18):13266-13279. PubMed ID: 37676021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the structure and immunostimulatory activity of a vaccine adjuvant, de-O-acylated lipooligosaccharide.
    Han JE; Wui SR; Kim KS; Cho YJ; Cho WJ; Lee NG
    PLoS One; 2014; 9(1):e85838. PubMed ID: 24465739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens.
    Swaminathan G; Thoryk EA; Cox KS; Meschino S; Dubey SA; Vora KA; Celano R; Gindy M; Casimiro DR; Bett AJ
    Vaccine; 2016 Jan; 34(1):110-9. PubMed ID: 26555351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diamino Allose Phosphates: Novel, Potent, and Highly Stable Toll-like Receptor 4 Agonists.
    Khalaf JK; Bess LS; Walsh LM; Ward JM; Johnson CL; Livesay MT; Jackson KJ; Evans JT; Ryter KT; Bazin-Lee HG
    J Med Chem; 2023 Oct; 66(20):13900-13917. PubMed ID: 37847244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced efficacy of a multi-epitope vaccine for type A and O foot‑and-mouth disease virus by fusing multiple epitopes with Mycobacterium tuberculosis heparin-binding hemagglutinin (HBHA), a novel TLR4 agonist.
    Lei Y; Shao J; Ma F; Lei C; Chang H; Zhang Y
    Mol Immunol; 2020 May; 121():118-126. PubMed ID: 32199211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
    Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
    Front Immunol; 2020; 11():575504. PubMed ID: 33117374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine adjuvant activity of emulsified oils from species of the Pinaceae family.
    Fox CB; Van Hoeven N; Granger B; Lin S; Guderian JA; Hartwig A; Marlenee N; Bowen RA; Soultanov V; Carter D
    Phytomedicine; 2019 Nov; 64():152927. PubMed ID: 31465981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic Glycolipids as Molecular Vaccine Adjuvants: Mechanism of Action in Human Cells and In Vivo Activity.
    Facchini FA; Minotti A; Luraghi A; Romerio A; Gotri N; Matamoros-Recio A; Iannucci A; Palmer C; Wang G; Ingram R; Martin-Santamaria S; Pirianov G; De Andrea M; Valvano MA; Peri F
    J Med Chem; 2021 Aug; 64(16):12261-12272. PubMed ID: 34382796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants.
    Reed SG; Hsu FC; Carter D; Orr MT
    Curr Opin Immunol; 2016 Aug; 41():85-90. PubMed ID: 27392183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant.
    Ishizaka ST; Hawkins LD
    Expert Rev Vaccines; 2007 Oct; 6(5):773-84. PubMed ID: 17931157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses.
    Fox CB; Moutaftsi M; Vergara J; Desbien AL; Nana GI; Vedvick TS; Coler RN; Reed SG
    Vaccine; 2013 Dec; 31(49):5848-55. PubMed ID: 24120675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.